Biotech Startups

Yunu offers a clinical trial imaging platform that harmonizes imaging workflows, data, and compliance from initial scan through trial submission, cutting turnaround times and reducing manual work. It serves sponsors, CROs, and cancer centers running oncology and other clinical trials, aligning radiology, oncology, and trial roles in a single system.

1 investor

Wuhan YZY Biopharma is a biotechnology company developing bispecific antibody (BsAb) therapies to treat cancer, cancer-related complications, and age-related ophthalmic diseases. It also develops preventive and therapeutic vaccines, including Y2019, a recombinant SARS-CoV-2 subunit protein vaccine developed with the Wuhan Institute of Virology.

1 investor

Zalvac develops innovative vaccines against bacterial infections using bacterial membrane vesicles as a platform, targeting pathogens like Streptococcus pneumoniae. The company is founded by leading microbiology researchers at Karolinska Institutet.

1 investor

Zavia Bio develops engineered proteins and peptides that act as biostimulants and biocontrol agents to help crops tolerate heat, drought, and other climate-related stress while reducing agrochemical use. It uses a proprietary platform combining bioinformatics, AI, and synthetic biology, with products including the Z-Active biostimulant and biocontrol agents in development.

1 investor

ZeaKal develops plant trait technologies that improve crop photosynthetic capacity to increase nutritional density, carbon capture, and resource efficiency, serving agricultural producers and energy companies seeking sustainable food and fuel production.

1 investor

Zehna Therapeutics is an early-stage biotech company developing non-bactericidal small-molecule inhibitors of gut microbial enzymes, with lead compounds targeting CutC lyase to lower TMAO levels. Its work focuses on treating cardiometabolic and chronic diseases, with chronic kidney disease as its lead indication.

1 investor

ZEMDRI (plazomicin) is an aminoglycoside antibiotic injection indicated for adults with complicated urinary tract infections, including pyelonephritis, caused by certain susceptible microorganisms. The product is a prescription pharmaceutical marketed by Cipla Therapeutics.

1 investor

Zene provides genetic testing and genome analysis services, along with a genome data analytics platform for health insights. The company serves individuals seeking personalized health information based on genomic data.

1 investor

ZenQMS provides a cloud-based electronic quality management system (eQMS) for life sciences and GxP-regulated organizations, with document control, audit, risk assessment, and validation capabilities. It includes validation and re-qualification documentation as part of a fixed implementation fee to support FDA compliance efforts.

1 investor

Zentek is a deep-science company developing three independent platforms: nuclear-grade graphite, graphene coatings, and aptamer biosciences. The company operates on a client-funded contract research organization (CRO) model, developing solutions for clients while retaining intellectual property ownership.

1 investor

Zeph develops a digital health platform with clinical-grade sensors to help patients manage respiratory conditions like COPD through home-based rehabilitation and evidence-based exercises. The platform serves patients, clinicians, and care teams seeking better respiratory health management.

1 investor

Zephyr AI is a healthcare technology company. The provided page content is a biography of Grant Verstandig and Red Cell Partners rather than a description of Zephyr AI itself, so it offers no usable detail about Zephyr AI's own products or market.

1 investor

1 investor

Zepto develops a targeted liquid biopsy platform for infectious disease diagnostics, offering plasma-based molecular testing through its CLIA reference laboratory and an integrated sample-to-result platform for use in hospital laboratories. It also provides analytical performance and reference testing support to help diagnostics obtain FDA clearance.

1 investor

Zerion is a pharmaceutical development company that uses its Dispersome formulation technology to improve the solubility and therapeutic performance of poorly soluble drugs. Spun out of the University of Copenhagen in 2019, it builds an internal drug pipeline while partnering with pharmaceutical companies to solve drug solubility challenges.

1 investor

1 investor

Zest Bio uses engineered microorganisms to convert low-value industrial fruit and vegetable processing waste — such as citrus peels, sugar beet pulp, potato peels, and grape pomace — into higher-value products. The company applies synthetic biology and green chemistry to agricultural byproducts.

1 investor

Zetagen develops molecular therapies, including its ZetaMet (Zeta-BC-003) drug, that aim to suspend cancer, inhibit pain, and regenerate bone in patients with metastatic and primary bone cancers. The locally administered treatments are adjunctive to other cancer therapies and target patients living with bone metastases, primarily in the United States.

1 investor

Zeteo Tech develops mass spectrometry and detection technologies for biomedical, defense, and security applications, including bioaerosol detection and breath analysis. The company works across areas such as TB and breath diagnostics and defense/security programs.

1 investor

ZEV Biotech develops IRIS®, an integrated molecular diagnostics platform combining reagents, hardware, and software that can test multiple genomic biomarkers across small batches of patient samples. It targets laboratories, research institutions, and hospitals, aiming to make molecular diagnostics accessible in decentralized settings, with a focus on Latin America.

1 investor

Zevra Therapeutics develops and commercializes rare disease treatments, including therapies for Niemann-Pick disease type C and urea cycle disorders. The company serves patients with inherited metabolic and genetic disorders through FDA-approved pharmaceutical products.

1 investor

Zeyton produces hydroxytyrosol-rich extracts from olives using a patented mechanical process without chemical transformations or solvents. The company supplies these natural polyphenol-based ingredients to food manufacturers for fortification of olive oils, margarines, dairy, and other consumer products.

1 investor

Shanghai Zhenge Biotech is an independent CDMO company providing contract development and manufacturing services for biopharmaceutical clients during clinical development and commercialization phases. The company offers a comprehensive range of services including drug development, cell line construction, process development, analytical methods, raw material production, drug formulation, stability studies, and animal cell culture media development.

1 investor

Zhongze Therapeutics is a drug discovery company developing innovative agents for psychiatric disorders, with a pipeline targeting unmet clinical needs in schizophrenia, depression, bipolar disorder, and autism through multi-target, multi-mechanism approaches. It focuses on the research, development, and commercialization of novel treatments in the central nervous system and psychiatric therapeutics space.

1 investor